New hope for ovarian cancer: Rina-S combo trial launches

NCT ID NCT07225270

First seen Nov 06, 2025 · Last updated May 07, 2026 · Updated 25 times

Summary

This study tests whether adding the experimental drug Rina-S to standard therapy helps keep ovarian cancer from coming back. About 528 people with platinum-sensitive ovarian cancer will receive either Rina-S alone, Rina-S plus bevacizumab, bevacizumab alone, or monitoring only. The goal is to see if the combination extends the time before the cancer progresses.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Hyogo Cancer Center

    RECRUITING

    Akashi, Hyōgo, Japan

  • Miami Valley Hospital South

    RECRUITING

    Centerville, Ohio, 45459, United States

  • Mie University Graduate School Of Medicine

    RECRUITING

    Tsu, Mie-ken, Japan

  • Mt. Sinai Comprehensive Cancer Center

    RECRUITING

    Miami, Florida, 33140, United States

  • National Hospital Organization Hokkaido Cancer Center

    RECRUITING

    Sapporo, Hokkaido, Japan

  • Niigata University Medical & Dental Hospital

    RECRUITING

    Niigata, Japan

  • Osaka Medical and Pharmaceutical University Hospital

    RECRUITING

    Takatsuki, Osaka, Japan

  • Saitama Medical University International Medical Center

    RECRUITING

    Hidaka, Saitama, Japan

  • Sapporo Medical University Hospital

    RECRUITING

    Sapporo, Hokkaido, Japan

  • The Cancer Institute Hospital of JFCR

    RECRUITING

    Tokyo, Japan

Conditions

Explore the condition pages connected to this study.